SCHEMBL2575682

SCHEMBL2575682

O=C(/C=C/c1ccccc1)CCl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.63
HAO1 Q9UJM8 1/20 0.63
MAPT P10636 5/20 0.59
LMNA P02545 5/20 0.59
RECQL P46063 3/20 0.59
HDAC3 O15379 2/20 0.59
HDAC4 P56524 2/20 0.59
HDAC1 Q13547 2/20 0.59
HDAC2 Q92769 2/20 0.59
HDAC8 Q9BY41 2/20 0.59
HDAC6 Q9UBN7 2/20 0.59
PLIN1 O60240 2/20 0.59
PLIN5 Q00G26 2/20 0.59
ABHD5 Q8WTS1 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
TNKS O95271 1/20 0.59
HCAR2 Q8TDS4 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC11 Q96DB2 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2575685 1.00 ALDH1A1 (0.63) ALDH1A1HAO1MAPTLMNARECQL
SCHEMBL12148877 0.85 HDAC3 (0.56) ALDH1A1HAO1MAPTLMNARECQL
SCHEMBL316674 0.85 HAO1 (0.84) ALDH1A1HAO1MAPTLMNARECQL
SCHEMBL3439644 0.85 HAO1 (0.84) ALDH1A1HAO1MAPTLMNARECQL
SCHEMBL13039630 0.83 ALDH1A1 (0.88) ALDH1A1HAO1MAPTLMNARECQL
SCHEMBL7657117 0.81 KMT2A (0.62) HAO1MAPTRECQLHDAC3HDAC4
SCHEMBL11269997 0.81 ALDH1A1 (0.66) ALDH1A1HAO1MAPTLMNARECQL
SCHEMBL11269994 0.81 ALDH1A1 (0.66) ALDH1A1HAO1MAPTLMNARECQL
SCHEMBL4440758 0.81 ALDH1A1 (0.66) ALDH1A1HAO1MAPTLMNARECQL
Methylene Chloride SCHEMBL28094578 0.81 CYP1A2 (0.83) ALDH1A1HAO1MAPTLMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021444-B2 Antiviral compounds Janssen Biopharma, Inc. (US) 2021-06-01 US disclosed
US-20190263754-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2019-08-29 US disclosed
US-10358453-B2 Antiviral compounds ALIOS BIOPHARMA, INC. (US) 2019-07-23 US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 US disclosed
US-20160244460-A1 ANTIVIRAL COMPOUNDS Janssen Pharmaceuticals, Inc. 2016-08-25 US disclosed
US-20160244460-A1 ANTIVIRAL COMPOUNDS Janssen Pharmaceuticals, Inc. 2016-08-25 US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 US disclosed
WO-2015026792-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2015-02-26 WO disclosed
US-RE42890-E1 Furazanobenzimidazoles BASILEA PHARMACEUTICA AG (CH) 2011-11-01 US disclosed
US-7385061-B2 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases BASILEA PHARMACEUTICA AG (CH) 2008-06-10 US disclosed
EP-1636215-B1 FURAZANOBENZIMIDAZOLES BASILEA PHARMACEUTICA AG (CH) 2008-01-23 EP disclosed
US-20070043061-A1 Furazanobenzimidazoles BASILEA PHARMACEUTICA AG 2007-02-22 US disclosed
EP-1636215-A1 FURAZANOBENZIMIDAZOLES Basilea Pharmaceutica AG (CH) 2006-03-22 EP disclosed
WO-2004103994-A1 FURAZANOBENZIMIDAZOLES BASILEA PHARMACEUTICA AG (CH) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263754-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 ALDH1A1 4011/4885HAO1 3644/4885MAPT 4665/4885
US-11021444-B2 Antiviral compounds MAVS, SARS1, ZC3HAV1 ALDH1A1 4011/4885HAO1 3644/4885MAPT 4665/4885
US-20180065932-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 ALDH1A1 4011/4885HAO1 3644/4885MAPT 4665/4885
US-10358453-B2 Antiviral compounds MAVS, SARS1, ZC3HAV1 ALDH1A1 4011/4885HAO1 3644/4885MAPT 4665/4885
US-20160244460-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 ALDH1A1 4011/4885HAO1 3644/4885MAPT 4665/4885
US-20150065504-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 ALDH1A1 4011/4885HAO1 3644/4885MAPT 4665/4885
US-20070043061-A1 Furazanobenzimidazoles FOXO1, CYP2F1, OXER1 ALDH1A1 335/4885HAO1 340/4885MAPT 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.